Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 11/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29920680 | 0.81 | AKR1B1 (0.37) | AKR1B1RIPK1RORCLMNAKDM4D | |
| SCHEMBL29920666 | 0.71 | RORC (0.35) | RORCCA12CA1CA7CA14 | |
| SCHEMBL29920644 | 0.71 | RORC (0.35) | RORCCA12CA1CA7CA14 | |
| SCHEMBL29920345 | 0.71 | AKR1B1 (0.37) | AKR1B1RORC | |
| SCHEMBL29920606 | 0.69 | AKR1B1 (0.40) | AKR1B1RORCCA12CA1CA7 | |
| SCHEMBL29920739 | 0.69 | AKR1B1 (0.40) | AKR1B1RORCCA12CA1CA7 | |
| SCHEMBL29920385 | 0.69 | MAP3K14 (0.39) | AKR1B1RORCLMNACA12CA1 | |
| SCHEMBL29920997 | 0.69 | CA12 (0.36) | AKR1B1RORCCA12CA1CA7 | |
| SCHEMBL29920625 | 0.68 | MAP3K14 (0.54) | AKR1B1RORCCA12CA1CA7 | |
| SCHEMBL29920679 | 0.67 | AKR1B1 (0.41) | AKR1B1RIPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2022217248-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ARSA, SNCA, F12 | AKR1B1 1824/4885RIPK1 4526/4885RORC 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.